Introduction
We are doctors looking after patients with blood disorders and scientists studying blood conditions in the lab. Our aim is to deliver the best expert and compassionate care for patients with blood diseases and patients who need blood cell transfusions. We want to reduce the burden of disease now and in the future, through our research, services, education, outreach and advocacy.
Our group includes international, scientific and clinical leaders. We draw on our combined expertise to carry out research and develop new services. Through our work we aim to:
- Improve the cost-effectiveness of cancer therapies and the outcomes of treatment – by developing new single cell approaches which tailor treatments to individuals. Find out more
- Improve the management of common and rare anaemias – by studying the role of iron and inflammation in anaemic patients, especially those who are elderly, and by developing a new national NHS service for patients with rare inherited red cell disorders. Find out more
- Improve the outcomes of blood cell and blood component transfusions – by using advanced e-tools and carrying out clinical trials to find out what approaches work best. Find out more
- Involve patients and carers in the key steps of our research projects. Find out more
Related websites
Oxford Centre for Haematology website: rdm.ox.ac.uk/och
RDM – HaemBio Biobank pages:
rdm.ox.ac.uk/about/our-clinical-facilities-and-mrc-units/och/haembio
NSSG website: nssg.oxford-haematology.org.uk
Introductory Talk by Haematology and Stem Cells Theme Lead Professor Paresh Vyas
Dr Susie Shapiro discusses research into thrombosis and COVID-19
In this webinar hosted by Thrombosis UK, BRC Haematology and Stem Cells theme researcher Dr Susie Shapiro speaks about her research on thrombosis in relation to COVID-19.
Follow the Oxford Centre for Haematology on Twitter
Did you know our #LymphomaManagement Course is suitable for trainees, consultants, specialist nurses & pharmacists? Join us in Sept to learn the essentials for the effective management of #lymphoma > https://t.co/zTMD0S69UM
@graham74GC @tobyeyre82 @OxfordHaem #LymSM #Haematology
Well done @ZPWLC and @SamanthaNier for highlighting the critical role of #PatientAdvocacy in #haematology at #EHA2022. #PPI @AcuteLeuk
A wonderful meeting this evening of our members and sponsors alongside the @EHA_Hematology conference #EHA2022.
@ZPWLC and @SamanthaNier sharing updates of ALAN #PatientAdvocacy activities
So nice to see everyone both in person and online!
Great talk by @beth_psaila at #EHA2022 adds important points about the interaction between megakaryocytes and stromal cells in #MPNsm.
That's a wrap! #EHA2022, fantastic science, being able to see old friends and making so many new, including this incredible lot @young_eha @MicrobiomDigest @MilsomMick @beth_psaila @AbAttacks @heatherEmachado @ElsyDutchy @krikirschner @awilkinsongroup
YoungEHA on Twitter
“This #EHA2022 we have meet in person (in some cases for the first time!) after two years working online 👏 We hope you've enjoyed the confer...
twitter.com
The best part of @EHA_Hematology #EHA2022 has been meeting up with people #TRTH #Vienna
And a great talk from the terrific but twitterless Dan Royston: machine learning assessment of megas and fibrosis in MPNs to predict patients are at high risk of fibrotic progression and potentially to monitor therapy response @UniofOxford @OxfordHaem @OUHospitals on MedRxiv
